Disclaimer

The trademark information displayed on this page is public information and is provided for informational purposes only. This information may be incomplete, inaccurate, or outdated, and IndiaFilings does not guarantee its accuracy. IndiaFilings is an independent platform and is not associated, affiliated, or connected with any trademark listed in this database. We do not represent or speak on behalf of any such trademark. If you are trying to contact a specific trademark, please use their official channels. IndiaFilings cannot assist with queries directed at other companies.

OXVOZID

Class 5Status: Expired
Application Number1753983
Trademark Status
ExpiredRenew Now
Trademark Class5
Application Date2008-11-14
Proprietor Name(1) SmithKline Beecham CorporationBody Incorporate
Appropriate OfficeDELHI
StateSTATE NOT SPECIFIED
Trademark TypeWORD
User DetailsProposed to be used
Agent NameANAND AND ANAND.[295]
Agent AddressB-41,NIZAMUDDIN EAST, NEW DELHI - 110 013.
Goods And Services Details[CLASS : 5] PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF CANCER.

Identical Trademarks

Similar trademarks found for this brand

1 found
BrandClassStatus
OXVOZID5Expired
Showing up to 6 identical trademarksView more on LEDGERS→

Trademark Protection

Automate the monitoring of your trademark application and filing of response to Government Objection or Hearing.

₹9,899+ GST

What's included:

✓
Brand Guard ( 1 application 1 class)
✓
Appointment of Lawyer
✓
Objection
✓
Hearing
✓
Infringement support (1)
✓
Power of Attorney (POA)

Frequently asked questions

Common questions about OXVOZID.

What is the status of trademark application 1753983?
The current status of trademark application 1753983 for OXVOZID is Expired.
What is the trademark class of OXVOZID?
OXVOZID is registered under trademark class 5.
Who is the proprietor of OXVOZID?
The proprietor of OXVOZID is (1) SmithKline Beecham CorporationBody Incorporate.
When was trademark application 1753983 filed?
Trademark application 1753983 for OXVOZID was filed on 2008-11-14.